Texas Attorney General Ken Paxton has launched a lawsuit against pharmaceutical giants Sanofi and Bristol-Myers Squibb, ...

Bristol-Myers Squibb Co. and Sanofi-Aventis on Thursday won a bid to stop Apotex Inc. from selling its cheaper generic version of the Plavix heart pill, the world’s second-biggest-selling medicine.

The cost of prescription medicines used by millions of people every day is about to plummet. The next 14 months will bring generic versions of seven of the world's 20 best-selling drugs, including the ...

Starting in October, drug companies will start rolling out generic versions of several widely used but expensive drugs. The top two sellers are the cholesterol drug Lipitor and the blood-thinner ...

Here's what's making health news this morning: FDA Approves Generic Version of Plavix (WSJ): The patent on the drug used to ward off heart attacks and strokes in people with cardiovascular disease ...

This article was originally on a blog post platform and may be missing photos, graphics or links. See About archive blog posts. The Food and Drug Administration said Friday that it will require a new ...

AP - The cost of prescription medicines used by millions of people every day is about to plummet. The next 14 months will bring generic versions of seven of the world's 20 best-selling drugs, ...

Texas Attorney General Ken Paxton claims that for decades the drugmakers failed to disclose that the medication is less ...

Generic competition will decimate sales of the brand-name drugs and slash the cost to patients and companies that provide health benefits. Top drugs getting generic competition by September 2012 are ...

Texas Attorney General Ken Paxton is suing Bristol-Myers Squibb Company and Sanofi-Aventis U.S and its related companies, ...

NEW YORK — An economics professor at the Massachusetts Institute of Technology testified Monday that there will be “significant price erosion” in the drug Plavix, even if a federal judge grants a ...

The marketers of the world's second-largest selling drug dodged a major threat to their revenues two months ago by reaching a deal to keep a generic competitor at bay until at least 2011. Now, 10 ...